FiercePharma1d
JPM25: Eli Lilly's preliminary '24 sales figures show a continued easing in breakneck GLP-1 market
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Eli Lilly & Co.: Positive Long-Term Outlook Despite Recent Setbacks – Buy Rating Affirmed
Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...
Southeast Missourian1d
Stock market today: Drops for Lilly and Big Tech weigh on Wall Street, even as most stocks rise
Eli Lilly and Big Tech losses drag U.S. indexes down despite overall market gains following positive inflation news. The S&P ...
Dayton Daily News1d
Stock market today: Most of Wall Street rises following encouraging inflation data, but Lilly drags
Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks kept indexes in check. The S&P 500 edged up 0.1% Tuesday, and three out of ...
Eli Lilly & Co: Strong Growth Prospects and Strategic Investments Justify Buy Rating
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geoff Meacham ...
JD Supra17h
Lilly v. FDA: Two Stories Collide to Make this GLP-1 Case a Tale of Our Time
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...
MarketBeat on MSN1d
Eli Lilly: 4 Reasons Investors Shouldn't Miss This Opportunity
Eli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with ...